Literature DB >> 30012803

Extended-release naltrexone overlooked in opioid use disorders guideline.

Launette M Rieb1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30012803      PMCID： PMC6050113          DOI： 10.1503/cmaj.69411

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  7 in total

1.  Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.

Authors:  James C Garbutt; Henry R Kranzler; Stephanie S O'Malley; David R Gastfriend; Helen M Pettinati; Bernard L Silverman; John W Loewy; Elliot W Ehrich
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

2.  Management of opioid use disorders: a national clinical practice guideline.

Authors:  Julie Bruneau; Keith Ahamad; Marie-Ève Goyer; Ginette Poulin; Peter Selby; Benedikt Fischer; T Cameron Wild; Evan Wood
Journal:  CMAJ       Date:  2018-03-05       Impact factor: 8.262

3.  Medications for opioid use disorder: bridging the gap in care.

Authors:  Nora D Volkow
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

4.  Cost and utilization outcomes of opioid-dependence treatments.

Authors:  Onur Baser; Mady Chalk; David A Fiellin; David R Gastfriend
Journal:  Am J Manag Care       Date:  2011-06       Impact factor: 2.229

5.  Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.

Authors:  Lars Tanum; Kristin Klemmetsby Solli; Zill-E-Huma Latif; Jurate Šaltyte Benth; Arild Opheim; Kamni Sharma-Haase; Peter Krajci; Nikolaj Kunøe
Journal:  JAMA Psychiatry       Date:  2017-12-01       Impact factor: 21.596

6.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

7.  American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

Authors:  Kyle Kampman; Margaret Jarvis
Journal:  J Addict Med       Date:  2015 Sep-Oct       Impact factor: 3.702
  7 in total
  1 in total

1.  Canadian Guidelines on Opioid Use Disorder Among Older Adults.

Authors:  Launette M Rieb; Zainab Samaan; Andrea D Furlan; Kiran Rabheru; Sid Feldman; Lillian Hung; George Budd; Douglas Coleman
Journal:  Can Geriatr J       Date:  2020-03-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.